| A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection (NCT06987318) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-12-01 |
| A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB) (NCT07595042) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-10-30 |
| Expanding HOPE Liver (NCT07778459) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-10-15 |
| A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV (NCT07124559) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-10-15 |
| A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies (NCT07569029) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-09-15 |
| Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults (NCT07757802) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-09-10 |
| Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study (NCT05652478) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (NCT05652504) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens) (NCT03895645) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States (NCT07027826) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (NCT07262983) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders (NCT07683104) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| BPL-1357 Against H1N1 Influenza Virus Challenge (NCT07215858) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| Modeling Host-Pathogen Interaction Using Lymphoid Organoids (NCT06479837) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM (NCT07775313) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-26 |
| A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine (NCT07703475) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-15 |
| Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates (NCT07703514) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-07 |
| Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection (NCT07706686) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-08-07 |
| Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG (NCT07611435) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-07-30 |
| A Safety Trial to Evaluate an Orally Ingested Yeast Modified to Express a Tetra-specific Anti-toxin for Clostridioides Difficile (NCT07649096) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-07-27 |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy (NCT07015996) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-07-15 |
| Small Trial of Alendronate Impact on the Reservoir of HIV (NCT07216794) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-07-08 |
| Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (NCT07040319) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-06-25 |
| Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy (NCT07416201) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-06-23 |
| Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (NCT06918990) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-05-27 |
| A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults (NCT07536308) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-05-26 |
| Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV (NCT06705478) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-05-17 |
| Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation (NCT07549503) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-05-14 |
| Dasatinib for HIV-1 Reservoir Reduction (NCT07342491) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-05-08 |
| Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza (NCT07215871) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-04-21 |
| Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy (NCT07103746) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-04-21 |
| THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins (NCT07271381) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-04-15 |
| LYmph Node eXamination in Cat Allergen Immunotherapy (NCT07447869) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-04-10 |
| Study of Oral Food Challenge Biomarkers (SAFER) (NCT07279467) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-04-01 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV (NCT07390474) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-25 |
| A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 (NCT07390955) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-19 |
| L9LS-R21 Interaction (NCT07208760) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-01 |
| Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial (NCT07199192) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-03-01 |
| Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (NCT07183709) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-02-02 |
| EVR and EPO for Liver Transplant Tolerance (NCT06832189) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-01-21 |
| Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (NCT06819176) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-01-20 |
| Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis (NCT07108387) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-01-05 |
| Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1 (NCT06517693) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-01-05 |
| A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (NCT07221162) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-12-05 |
| Improving Physical Ability and Cellular Senescence Elimination in HIV (NCT07144293) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-12-04 |
| Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans (NCT06845358) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-11-26 |
| Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus (NCT04370795) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-11-26 |
| Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis (NCT07202598) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-11-12 |
| Microbiome and Atopy in Mali (NCT07051902) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-30 |
| Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) (NCT06919003) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-22 |
| First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (NCT07169318) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-16 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706 (NCT06665646) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-14 |
| pH1N1 Blinded Challenge Study (NCT07110532) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-10 |
| Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load (NCT06974877) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-10 |
| Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (NCT07113743) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-10 |
| Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART (NCT06908083) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-09-08 |
| Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults (NCT07111078) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-08-27 |
| Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults (NCT07095231) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-08-11 |
| A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV (NCT06919016) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-08-06 |
| First-in-Human PfSPZ-LARC2 Vaccination/CHMI (NCT06735209) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-23 |
| L9LS in Women of Childbearing Potential in Mali (NCT07060508) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-22 |
| Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (NCT06959771) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-16 |
| A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection (NCT05582694) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-10 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV (NCT06905275) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-07 |
| A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults (NCT07019883) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-06-12 |
| Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori (NCT06871579) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-06-11 |
| Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection (NCT06908096) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-05-29 |
| Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (NCT06504160) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-05-22 |
| Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers (NCT06945276) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-05-13 |
| Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy (NCT06851767) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-05-09 |
| CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy (NCT06336434) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-05-01 |
| Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults (NCT06863142) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-04-28 |
| Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy (NCT06680479) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-04-01 |
| Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (NCT06692907) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-03-31 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health (NCT06796686) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-03-17 |
| Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients (NCT06476132) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-03-12 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (NCT06192160) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-03-11 |
| Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients (NCT06730126) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-03-10 |
| A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV (NCT06812494) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-03-07 |
| Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults (NCT06745921) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-02-24 |
| A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus (NCT06118515) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-02-19 |
| Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (NCT06709521) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-02-12 |
| Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents (NCT06477653) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-02-05 |
| Belatacept in Heart Transplantation (NCT06478017) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-01-29 |
| A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up (NCT06732414) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-01-28 |
| Skin Immunity Sample Collection Involving Blisters and Biopsies (NCT03921515) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-12-09 |
| Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays (NCT06607003) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-11-26 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV (NCT06557785) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-11-25 |
| The Tatelo Plus Study (NCT06508749) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-11-11 |
| A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia (NCT05600920) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-11-06 |
| Characterization of Human Immune Signatures to Zoonotic Virus Exposure in Cambodia (NCT06680843) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-11-01 |
| CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR (NCT06560684) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-29 |
| Cardamom and Topical Roseomonas in Atopic Dermatitis (NCT06096857) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-09 |
| A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum (NCT06267872) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-07 |
| Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults (NCT06585891) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-07 |
| High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients (NCT05947071) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-09-26 |
| Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (NCT06805487) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-09-24 |
| The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (NCT06551506) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-09-19 |
| Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (NCT06280950) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-09-12 |
| A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission (NCT05719441) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-08-19 |